<p>A three-dose course of AstraZeneca's Covid-19 vaccine, Covishield in India, is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.</p>.<p>The study, yet to be published in a peer-reviewed medical journal, showed antibody levels against Omicron after the booster shot were higher than antibodies in people who had been infected with and recovered naturally from Covid-19.</p>.<p>After a three-dose course of the vaccine, neutralising levels against Omicron were similar to those against the virus's Delta variant after two doses, the company added.</p>.<p>The Anglo-Swedish drugmaker said researchers at Oxford University who carried out the study were independent from those who worked on the vaccine, Vaxzevria, with AstraZeneca.</p>.<p><strong>Check out DH's latest videos</strong></p>
<p>A three-dose course of AstraZeneca's Covid-19 vaccine, Covishield in India, is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.</p>.<p>The study, yet to be published in a peer-reviewed medical journal, showed antibody levels against Omicron after the booster shot were higher than antibodies in people who had been infected with and recovered naturally from Covid-19.</p>.<p>After a three-dose course of the vaccine, neutralising levels against Omicron were similar to those against the virus's Delta variant after two doses, the company added.</p>.<p>The Anglo-Swedish drugmaker said researchers at Oxford University who carried out the study were independent from those who worked on the vaccine, Vaxzevria, with AstraZeneca.</p>.<p><strong>Check out DH's latest videos</strong></p>